EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Brazilin From Biancaea sappan as a Multi‐Target Candidate in Thalassaemia: Mechanistic Insights Into Iron Chelation, Antioxidant Activity, and Potential JAK2 Modulation

Racy Youngest iD, Yusof Kamisah, Ratu Safitri, Ani Melani Maskoen

Clinical and Experimental Pharmacology and Physiology · 2026-08 · 53 (8)

DOI: 10.1111/1440-1681.70145 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, online erschienen am 10.08.2026. Verfasst von Racy Youngest und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biotechnology Doctoral Program, Universitas Padjadjaran, Bandung, Indonesia. Hauptthemen laut MEDLINE: Janus Kinase 2, Antioxidants, Iron Chelating Agents, Thalassemia. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Padjadjaran Doctoral Postgraduate Scholarship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thalassaemia is a hereditary haemoglobinopathy characterised by impaired globin synthesis, resulting in ineffective erythropoiesis and systemic iron overload. While current management relies on blood transfusions and chelation, these often fail to address the underlying molecular signalling dysregulation that contributes to the disease's progression, such as the imbalance in erythropoietin production and the activation of inflammatory pathways. Brazilin, the primary homoisoflavonoid from Biancaea sappan L., presents a multifaceted therapeutic profile. This review synthesises evidence of brazilin's activity as a potent iron chelator and reactive oxygen species (ROS) scavenger and anti‐inflammatory agent, while evaluating its potential as a novel JAK2 inhibitor. Molecular docking suggests brazilin may bind to the JAK2 ATP‐binding pocket, though functional validation is still required. By modulating the erythroferrone (ERFE)–hepcidin (HAMP) axis, brazilin potentially restores iron homeostasis and mitigates splenomegaly. We further evaluate its pharmacokinetics and safety profile, highlighting low toxicity and high oral bioavailability. This positions brazilin as a promising lead candidate for thalassaemia adjunct treatment, warranting further in vivo validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase 2AntioxidantsIron Chelating AgentsThalassemiaBenzopyransHumansAnimals

Stichwörter der Autor:innen

Biancaea sappan L.JAK2 inhibitorJAK2/STAT5 pathwayantioxidantanti‐inflammatorybraziliniron overload

Substanzen

Janus Kinase 2AntioxidantsbrazilinIron Chelating AgentsBenzopyrans

Autor:innen und Institutionen

  • Biotechnology Doctoral Program, Universitas Padjadjaran, Bandung, Indonesia.
  • Department of Pharmacology, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
  • Department of Biology, Universitas Padjadjaran, Sumedang, Indonesia.
  • Faculty of Dentistry, Universitas Jenderal Achmad Yani, Cimahi, Indonesia.

ORCID-Profile: Racy Youngest

Förderung

  • Padjadjaran Doctoral Postgraduate Scholarship

Zitieren

APA

Youngest, R., Kamisah, Y., Safitri, R., & Maskoen, A. M. (2026). Brazilin From Biancaea sappan as a Multi‐Target Candidate in Thalassaemia: Mechanistic Insights Into Iron Chelation, Antioxidant Activity, and Potential JAK2 Modulation. Clinical and Experimental Pharmacology and Physiology, 53(8). https://doi.org/10.1111/1440-1681.70145

Vancouver

Youngest R, Kamisah Y, Safitri R, Maskoen AM. Brazilin From Biancaea sappan as a Multi‐Target Candidate in Thalassaemia: Mechanistic Insights Into Iron Chelation, Antioxidant Activity, and Potential JAK2 Modulation. Clinical and Experimental Pharmacology and Physiology. 2026;53(8). doi:10.1111/1440-1681.70145

BibTeX
@article{Youngest2026,
  author = {Youngest, Racy and Kamisah, Yusof and Safitri, Ratu and Maskoen, Ani Melani},
  title = {Brazilin From Biancaea sappan as a Multi‐Target Candidate in Thalassaemia: Mechanistic Insights Into Iron Chelation, Antioxidant Activity, and Potential JAK2 Modulation},
  journal = {Clinical and Experimental Pharmacology and Physiology},
  year = {2026},
  volume = {53},
  number = {8},
  doi = {10.1111/1440-1681.70145}
}
Kostenlos starten →